Lake Street initiated coverage on OncoCyte with a new price target
$OCX
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Lake Street initiated coverage of OncoCyte with a rating of Buy and set a new price target of $5.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/28/2025 | $5.00 | Buy | Lake Street |
| 5/24/2022 | Overweight → Equal-Weight | Stephens | |
| 3/14/2022 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 3/11/2022 | $11.00 → $6.00 | Buy | Lake Street |
| 3/11/2022 | $5.00 → $4.00 | Buy | Needham |
| 1/7/2022 | $3.10 | Overweight | Stephens & Co. |
| 1/6/2022 | $3.10 | Overweight | Piper Sandler |
| 12/16/2021 | $7.00 → $5.00 | Buy | Needham |